Last €0.74 EUR
Change Today -0.007 / -0.93%
Volume 33.0
BHN On Other Exchanges
As of 3:16 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

bellus health inc (BHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - €1.33
52 Week Low
02/10/14 - €0.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BELLUS HEALTH INC (BHN)

Related News

No related news articles were found.

bellus health inc (BHN) Related Businessweek News

No Related Businessweek News Found

bellus health inc (BHN) Details

BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. Its clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome related to shiga toxin-producing E. coli bacterial infections. The company also has an agreement with AmorChem Holdings Inc. to develop drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

8 Employees
Last Reported Date: 02/27/14
Founded in 1993

bellus health inc (BHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$315.9K
Vice President of Finance
Total Annual Compensation: C$170.7K
Senior Vice President of Drug Development
Total Annual Compensation: C$321.8K
Vice President of Business Development
Total Annual Compensation: C$175.0K
Compensation as of Fiscal Year 2013.

bellus health inc (BHN) Key Developments

BELLUS Health Inc. Announces Sale of ABCP Notes and Settlement of Credit Facilities

BELLUS Health Inc. announced the sale of its ABCP Notes and settlement of its credit facilities. The company sold all of its asset-backed commercial paper notes (ABCP Notes) for a total consideration of $5.3 million and used the proceeds thereof to settle its credit facilities, which were scheduled to mature in April 2016. Net cash generated from these transactions amounted to $150,000. Early settlement of its credit facilities will enable the company to save approximately $150,000 in future interest payments, and fully eliminates its bank indebtedness. The sale of ABCP Notes also eliminates the market risk associated with these assets.

BELLUS Health Inc. Announces Earnings Results for the Third Quarter September 30, 2014

BELLUS Health Inc. announced earnings results for the third quarter September 30, 2014. For the quarter, the company’s revenues amounted to CAD 420,000 compared to CAD 528,000 for the corresponding period the previous year. The decrease is mainly attributable to revenue recorded in the comparative period in relation to the agreement with Asclepios Bioresearch (UK) Limited for the development of BLU8499, which was terminated in October 2013. Net finance income amounted to CAD 53,000 compared to CAD 129,000 for the corresponding period the previous year. The decrease is mainly attributable to a lower increase in the fair value of the ABCP Notes compared to the previous year. Net loss attributable to shareholders was CAD 710,000 or CAD 0.01 per basic and diluted share compared to net profit attributable to shareholders of CAD 1,039,000 or CAD 0.02 per basic and diluted share for the corresponding period the previous year.

BELLUS Health Reports Consolidated Results for Second Quarter Ended June 30, 2014

BELLUS Health Inc. reported consolidated earnings results for second quarter ended June 30, 2014. For the quarter, the company’s revenues were CAD 420,000 against CAD 383,000 a year ago. Net loss attributable to shareholders was CAD 737,000 against CAD 867,000 a year ago. Basic and diluted loss per share was CAD 0.02 against CAD 0.02 a year ago. Revenues mainly consist of revenue recognized for accounting purposes from the asset sale and license agreement and the service agreement entered into with Auven Therapeutics in 2010 in relation to KIACTA(TM). Net finance income amounted to CAD 28,000 for the three-month period ended June 30, 2014, compared to CAD 104,000 for the corresponding period the previous year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHN:GR €0.74 EUR -0.007

BHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.11 CAD +0.015
Eli Lilly & Co $72.00 USD -0.11
Novartis AG SFr.90.15 CHF -0.85
Pfizer Inc $31.25 USD -0.58
View Industry Companies

Industry Analysis


Industry Average

Valuation BHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.9x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BELLUS HEALTH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at